"We found that adding vitamin D substantially reduced the production of the protein driving the allergic response and also increased production of the protein that promotes tolerance," said Dr. Kolls, who also is professor and chair of genetics at LSU Health Sciences Center New Orleans. "Based on our results, we have strong rationale for a clinical trial of vitamin D to determine whether it can prevent or treat ABPA in patients with cystic fibrosis."
Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide), according to the Cystic Fibrosis Foundation. A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that clogs the lungs and leads to life-threatening lung infections and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food.
"These important findings by Dr. Kolls' team add to the growing body of evidence showing that vitamin D may play a critical role on immune responses and allergic diseases," said Juan Celedon, M.D., Dr.P.H., chief of the Division of Pulmonary Medicine, Allergy and Immunology at Children's Hospital.
